What is Alternative Biomedical Solutions?
Founded in 2015, Alternative Biomedical Solutions is dedicated to enhancing human health and product safety by offering comprehensive technology and services. ABS provides unbiased, OEM-neutral solutions designed to foster innovation, complemented by state-of-the-art reference laboratory services. The company serves a broad spectrum of industries, encompassing toxicology, pain management, drug rehabilitation, criminal justice, forensic, environmental, and cannabis markets, among others. As a portfolio company of Centre Lane Partners, ABS leverages strategic backing to drive its mission forward.
How much funding has Alternative Biomedical Solutions raised?
Alternative Biomedical Solutions has raised a total of $16M across 2 funding rounds:
Debt
$1M
Angel/Seed
$15M
Debt (2020): $1M with participation from PPP
Angel/Seed (2022): $15M led by Sequoia China Seed Fund, Eight Roads Ventures, and F-Prime Capital Partners
Key Investors in Alternative Biomedical Solutions
Eight Roads Ventures
Eight Roads, headquartered in Kent, is a venture capital investment company specializing in real estate, venture, and growth businesses.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
Sequoia China Seed Fund
Undisclosed investor participating in the funding round.
What's next for Alternative Biomedical Solutions?
The recent major strategic investment in Alternative Biomedical Solutions signals a pivotal growth phase for the company. With a robust foundation in providing advanced technological and laboratory services across critical health and safety sectors, ABS is well-positioned to expand its market reach and deepen its impact. Future endeavors will likely focus on scaling operations, further developing its innovative solutions, and potentially exploring new market opportunities within the rapidly evolving biomedical landscape. The company's commitment to unbiased, OEM-neutral approaches suggests a continued focus on technological advancement and client-centric service delivery.
See full Alternative Biomedical Solutions company page
